A Phase II Study of Neoadjuvant Chemoradiotherapy with Docetaxel, Cisplatin and 5-FU Followed by Surgical Resection in the Treatment of Locally Advanced Esophagogastric Junction Cancer and Locally Advanced Esophageal Cancer

“`html

Phase II Study Summary

A clinical trial was conducted to evaluate the effectiveness and safety of using a specific chemotherapy and radiotherapy regimen followed by surgery in treating advanced esophageal cancer.

Practical Solutions and Value

• The study enrolled 24 newly diagnosed esophageal cancer patients to assess the treatment approach.
• The treatment involved a specific radiotherapy regimen and chemotherapy protocol.
• The primary endpoints were disease-free survival, overall survival, and evaluation of hematologic toxicity.
• The study population had a median age of 55.5 years, with over 90% of the patients being male.
• The 5-year disease-free survival was 37.1%, and the 5-year overall survival was 48.7%.
• The pathologic complete response rate was 45.8%.
• The most common toxicities were leukopenia and thrombocytopenia, but no severe hematologic toxicity was reported.
• The use of the specific treatment regimen demonstrated tolerable toxicity and achieved acceptable disease-free and overall survival outcomes.

“`

Full research A Phase II Study of Neoadjuvant Chemoradiotherapy with Docetaxel, Cisplatin and 5-FU Followed by Surgical Resection in the Treatment of Locally Advanced Esophagogastric Junction Cancer and Locally Advanced Esophageal Cancer: https://pubmed.ncbi.nlm.nih.gov/38666809/?utm_source=Feedly&utm_medium=rss&utm_campaign=None&utm_content=1B1L42DK3a-JWCV4P_PtHHBmWjwBLFNcDXsYJkbqjQD0Ca7UQh&fc=None&ff=20240426163055&v=2.18.0.post9+e462414